PDF Print E-mail

Posters and Presentations

June 2017: American Society of Clinical Oncology (ASCO) Annual Meeting

  • Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View poster

April 2017: American Association for Cancer Research (AACR) Annual Meeting

  • IFN-γ Analysis in Blood and Tissue as a Potential Prognostic and/or Predictive Biomarker. View poster
  • Targeting Phosphatidylserine in Combination with Adoptive T cell Transfer Eliminates Advanced Tumors Without Off-Target Toxicities in a Melanoma Preclinical Model. View poster
  • Phosphatidylserine Targeting Antibody in Combination With Tumor Radiation and Immune Checkpoint Blockade Promotes Anti-tumor Activity in Mouse B16 Melanoma. View poster
  • Monoclonal Antibodies Targeting Phosphatidylserine Augment Combinational Activity of LAG3 and PD-1 Targeting Antibodies In Murine TNBC Through Enhanced Reprogramming of the Immunosuppressive Tumor Microenvironment. View poster

November 2016: Society for the Immunotherapy of Cancer (SITC) Annual Meeting

  • Phosphatidylserine Targeting Antibody in Combination with Checkpoint Blockade and Tumor Radiation Therapy Promotes Anti-cancer Activity In Mouse Melanoma. View poster
  • Monoclonal Antibodies Targeting Phosphatidylserine Enhance Combinational Activity of LAG3 and PD-1 Targeting Antibodies and Establish Specific Long Term Tumor Surveillance in Murine Breast Cancers. View poster
  • Anti-tumor Responses by Ibrutinib and Anti-PD-1 Blockade is Enhanced by PS-Targeting Antibody Therapy. View poster

April 2016: American Association for Cancer Research (AACR) Annual Meeting

  • Phosphatidylserine Targeting Antibodies Augment the Anti-Tumorigenic Activity of Anti-PD-1 Therapy by Enhancing Immune Activation and Downregulating Pro-Oncogenic Factors Induced by T-Cell Checkpoint Inhibition in Murine Triple Negative Breast Cancers. View poster

November 2015: Society for Immunotherapy of Cancer (SITC) Annual Meeting

  • Targeting of Phosphatidylserine by Monoclonal Antibodies Augments the Activity of anti-PD-1 Therapy in Triple Negative Breast Carcinoma Murine Models. View poster
  • Targeting Phosphatidylserine Synergizes with Immune Checkpoint Blockade by Inducing De Novo Tumor Specific Immunity. View poster
  • New Method for ImmunoProfiling the Tumor Microenvironment of Cancer Patients by OpalTM Multiplex Quantitative Immunofluorescence (IF)Assays. View poster

October 2015: American Society for Radiation Oncology (ASTRO) Annual Meeting

  • Preliminary Results From a Phase I Trial of Radiation Therapy, Capecitabine, and the Phosphatidylserine-Targeting Antibody Bavituximab in the Neoadjuvant Treatment of Rectal Adenocarcinoma. View Poster

September 2015: The 16th World Conference on Lung Cancer (WCLC)

  • Bavituximab Activates CD8+ TILs in a 3D Ex Vivo System of Lung Cancer Patient Derived Tumors With Negative PD-L1 Expression. View presentation
  • SUNRISE: A Phase III, Randomized, Double-blind, Placebo-Controlled Multi-center Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer. View poster
  • Targeting phosphatidylserine-mediated immune suppression enhances the efficacy of immune checkpoint blockade in pre-clinical tumor models. View presentation

August 2015: 10th Annual Immunotherapy and Vaccine Summit (ImVacs)

  • Expansion and Activation of T Cells via the Targeting of the Immunosuppressive Ligand Phosphatidylserine (PS): Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy. View presentation

May 2015: American Society of Clinical Oncology (ASCO) Annual Meeting

  • Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer. View poster
  • Activation of CD8+ tumor infiltrating lymphocytes by bavituximab in a 3D ex vivo system of lung cancer patients. View poster
  • A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC). View poster

April 2015: American Association for Cancer Research (AACR) Annual Meeting

  • Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer. View poster
  • Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of immune checkpoint blockades in K1735 and B16 mouse melanoma models. View poster
  • Targeting of Phosphatidylserine by Monoclonal Antibodies Enhances the Activity of Immune Checkpoint Inhibitors in Breast Tumors. View poster

March 2015: Immune Checkpoint Inhibitors: Validate Novel Pathways, Discover Predictive Biomarkers, Optimize Clinical Strategy

  • Expansion and Activation of T-cells via the Targeting of the Immunosuppressive Ligand Phosphatidylserine: Combination Strategy with Other Checkpoint Inhibitors View slide presentation

March 2015: Society of Surgical Oncology 68th Annual Cancer Symposium

February 2015: Keystone Symposium: Tumor Immunology: Multidisciplinary Science Driving Combination Therapy

  • Antibody-mediated Blockade of Phosphatidylserine Enhances the Anti-tumor Activity of Immune Checkpoint Inhibitors by Affecting Myeloid Derived Suppressor Cells (MDSC) and Lymphocyte Populations in the Tumor Microenvironment. View poster
  • Phosphatidylserine-targeting Antibody Enhances the Anti-Tumor Activity of Immune Checkpoint Inhibitors. View slide presentation

January 2015: Global Technology Community (GTC) 7th Immunotherapeutics & Immunomonitoring Conference

  • Blockade of PS Enhances the Anti-tumor Activity of Targeted Therapy & Immune Checkpoint Inhibitors by Reducing Immunosuppressive Inflammatory Cells in the Tumor Microenvironment. View slides

January 2015: ASCO Gastrointestinal Cancers Symposium

  • A Phase II Study of Bavituximab and Sorafenib in Advanced Hepatocellular Carcinoma (HCC). View poster

December 2014: San Antonio Breast Cancer Symposium (SABCS)

  • Antibody-mediated Blockade of Phosphatidylserine Enhances the Anti-tumor Activity of Immune Checkpoint Inhibitor α-PD-1 by Affecting Myeloid Derived Suppressor Cells (MDSC) and Lymphocyte Populations in a Breast Tumor Microenvironment. View poster

November 2014: 29th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC)

  • Correlative studies of a Phase II study of Bavituximab and Sorafenib in Patients with Advanced Hepatocellular Carcinoma. View Poster
  • Antibody-mediated Blockade of Phosphatidylserine Enhances the Anti-tumor Activity of Immune Checkpoint Inhibitor anti-CTLA-4 by Affecting Myeloid Derived Suppressor Cells (MDSC) and Lymphocyte Populations in a Melanoma Tumor Microenvironment. View poster
  • Antibody-mediated Blockade of Phosphatidylserine Enhances the Anti-tumor Activity of Immune Checkpoint Inhibitor a-PD-1 by Affecting Myeloid Derived Suppressor Cells (MDSC) and Lymphocyte Populations in a Melanoma Tumor Microenvironment. View poster
  • Antibody-mediated Blockade of Phosphatidylserine Enhances the Anti-tumor Activity of Immune Checkpoint Inhibitor a-PD-1 by Affecting Myeloid Derived Suppressor Cells (MDSC) and Lymphocyte Populations in a Breast Tumor Microenvironment. View poster

October 2014: Chicago Multidisciplinary Symposium in Thoracic Oncology

  • A phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy naïve stage IV non-squamous non-small cell lung cancer. View poster

October 2014: Cancer Research Institute (CRI), "Cancer Immunotherapy: Out of the Gate”

  • Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of immune checkpoint inhibitors by affecting myeloid-derived suppressor cell (MDSC) and lymphocyte populations in the tumor microenvironment. Poster presentation by Dr. Rolf Brekken. View poster

August, 2014: ImVacS, the 9th Annual Immunotherapies and Vaccine Summit

  • Phosphatidylserine (PS)-Targeting Antibodies Enhance Activity of Immune Checkpoint Inhibitors by Repolarizing Immunosuppressive Immune Cells Populating the Tumor Microenvironment. presentation by Jeff Hutchins. View Presentation

May, 2014: Cancer Research Institute Webinar

  • Breakthroughs in Cancer Immunotherapy: Dr. Rolf Brekken, Reactivating Your Immune System to Fight Cancer. View webinar

April, 2014: AACR Annual Meeting

  • Antibody-mediated blockade of phosphatidylserine combined with radiation improves survival and tumor eradication in a rat model of non-small cell lung cancer. View poster
  • Phosphatidylserine-targeting antibody synergizes with anti-PD-1 antibody to inhibit tumor growth in K1735 mouse melanoma model. View poster
  • Targeting of Phosphatidylserine by Monoclonal Antibodies Enhances Activity of Immune Checkpoint Inhibitors in Tumors. View poster

March, 2014: Keystone Symposium: Immune Evolution in Cancer

 

  • Phosphatidylserine-Targeting Antibodies Induce M1 Macrophage Polarization, Promote Myeloid Derived Suppressor Cell Differentiation and Boost Tumor- Specific Immunity. View poster
  • Phosphatidylserine Targeting Antibodies Enhance the Activity of Immune Checkpoint Inhibitors in Tumors. View poster

March, 2014: Keystone Symposium: HIV Pathogenesis - Virus vs. Host

  • Phosphotidylserine-targeting antibody Triggers β-Chemokine Release from Monocytes by Cell-Cell Crosslinking and is a potent inhibitor of HIV-1 in vitro. View poster

March, 2014: ITOC-1 Immunotherapy of Cancer Conference

June, 2013: ASCO Annual Meeting Posters

  • Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer. View poster
  • Phase I clinical trial of bavituximab and paclitaxel in patients with HER2-negative metastatic breast cancer. View poster
  • Randomized, open-label, phase II trial of gemcitabine with or without bavituximab in patients with nonresectable stage IV pancreatic adenocarcinoma. View poster

November, 2013: Society for Immunotherapy of Cancer Annual Meeting

  • Targeting of Phosphatidylserine by Monoclonal Antibodies Induces Innate and Specific Anti-tumor Responses. View poster
  • Phosphatidylserine-Targeting  Antibody  Induces  M1  Macrophage  Polarization,  Promotes  Myeloid  Derived   Suppressor  Cell  Differentiation,  Boosts  Tumor-­Specific  Immunity. View poster

April, 2013: AACR Annual Meeting

  • Phosphatidylserine-targeting antibody reactivates tumor immunity and destroys tumor vasculature in mice. View poster
  • Predicting Anti-tumor Responses to Phosphatidylserine Targeting Antibodies Using Tumor Imaging. View poster
  • Phosphatidylserine-Targeting ‘Betabodies’ for the Treatment of Cancer. View poster

May, 2012: New York Academy of Sciences Symposium

Phosphatidylserine Asymmetry and Cell Survival: Therapeutic Applications in Cancer and Infectious Disease

On May 1, 2012, the New York Academy of Sciences (NYAS) hosted a symposium covering the topics of the role that phosphatidylserine (PS) plays in suppressing immune response and therapeutic applications of targeting PS. Philip Thorpe, PhD, inventor or Peregrine's PS-targeting antibody technology and scientific advisor to the company, gave the final presentation, titled, Targeting Tumor Vasculature and Reactivating Tumor Immunity with Bavituximab. The entire symposium including audio replay and presentation slides are available o n the NYAS website here.

November, 2012: Society for Immunotherapy of Cancer Annual Meeting

  • Targeting of Phosphatidylserine by Monoclonal Antibodies Induces Innate and Specific Anti-tumor Responses. View poster

April, 2012: AACR Annual Meeting Clinical Poster Presentations

  • A phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy naïve stage IV non-squamous non-small cell lung cancer. View poster
  • A Phase I Study of Bavituximab and Sorafenib in Patients with Advanced Hepatocellular Carcinoma. View poster
  • Microparticle Generation and Activation after Treatment with Paclitaxel and Bavituximab Combination Therapy in Metastatic Breast Cancer. View poster

April, 2012: AACR Annual Meeting Preclinical Poster Presentations

  • Tumor Detection and Measurement of Responses to Chemotherapy Using Human Phosphatidylserine Targeting Antibody Fragments. View poster
  • Cure of castration-resistant prostate cancer in TRAMP mice by reactivating tumor immunity with a phosphatidylserine-targeting antibody. View poster
  • Increased Fc-FcR Interaction of Human Phosphatidylserine Targeting Antibody Enhances Pro-Inflammatory and ADCC Mechanisms. View poster
  • In Vivo Binding of chTNT-1/B Antibodies (Cotara) to DNA/Histone Complexes in Tumors Using Near-Infrared Optical Imaging. View poster

June, 2012: AACR Pancreatic Cancer Conference: Progress and Challenges

  • A randomized, open-label phase 2 trial of gemcitabine with or without bavituximab in patients with previously untreated stage IV pancreatic cancer. View poster

September, 2011: World Molecular Imaging Congress Poster Presentations

  • Imaging of Human Tumor Xenografts in Mice Using Near-Infrared Fluorescent-Labeled Phosphatidylserine Targeting Antibodies View poster...
  • Multimodal Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model View poster...

April, 2011: AACR Annual Meeting Poster Presentations:

  • Prostate Cancer: Targeting Phosphatidylserine to Improve Hormone Therapy of Prostate Cancer. View poster...
  • Advanced Liver Cancer: Phosphatidylserine-Targeting Antibody Combined with Sorafenib has Strong Anti-Tumor Activity Against Human Hepatocellular Carcinomas in Mice. View poster...
  • Mechanism of Action: Phosphatidylserine-Targeting Antibody Induces Differentiation of Myeloid-Derived Suppressor Cells into M1-Like Macrophages. View poster...
  • Prostate Cancer: PS-Targeting Antibody Enhances Survival Benefit of Androgen Deprivation Therapy of Mice Bearing Syngeneic Prostate Cancer. View poster...

April, 2010: AACR Annual Meeting Poster Presentations:

  • Mechanism of Action: Phosphatidylserine on Dying Tumor Cells Suppresses Dendritic Cell Activation and Inhibits Tumor Immunity: Reversal with PS-Targeting Antibody. View poster...
  • Imaging: Phosphatidylethanolamine is a marker of tumor vasculature and can be used as a target for optical imaging. View poster...
  • Imaging: Monitoring Tumor Response to Chemotherapy by In Vivo Real-Time Imaging of Phosphatidylserine-Targeting Antibodies. View poster...

Bavituximab in Action

Experiments in animals have shown that bavituximab recruits immune cells into the tumor environment.


Before Therapy

After Therapy
Key
Blue: tumor cell nuclei
Red: blood vessels
Green: immune cells (macrophages)

Read about the growing body of published research validating bavituximab’s broad-spectrum potential...